70 participants
Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- Study Type:
- OBSERVATIONAL
- Last Updated:
- 2026-07-24
- Start Date:
- 2026-03-30
- Completion:
- 2029-03-30
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
No Results Yet